PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma

Blood

Volumn 122, Issue 15, 2013, Pages 2683-2693

  Boi, Michela ^a   Rinaldi, Andrea ^a   Kwee, Ivo ^a,b,c   Bonetti, Paola ^a   Todaro, Maria ^d   Tabbò, Fabrizio ^d   Piva, Roberto ^d,e   Rancoita, Paola M V ^a,b   Matolcsy, András ^f   Timar, Botond ^f   Tousseyn, Thomas ^g   Rodríguez Pinilla, Socorro Maria ^h   Piris, Miguel A ^h   Beà, Sílvia ⁱ   Campo, Elias ⁱ   Bhagat, Govind ^j   Swerdlow, Steven H ^k   Rosenwald, Andreas ^l   Ponzoni, Maurilio ^m   Young, Ken H ⁿ   Piccaluga, Pier Paolo ^o   Dummer, Reinhard ^p   Pileri, Stefano ^o   Zucca, Emanuele ^a   Inghirami, Giorgio ^d,e,q   Bertoni, Francesco ^a   more..

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b DALLE MOLLE INSTITUTE FOR ARTIFICIAL INTELLIGENCE IDSIA   (Switzerland)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^d UNIVERSITY OF TURIN   (Italy)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SEMMELWEIS UNIVERSITY   (Hungary)

^g UNIVERSITY OF LEUVEN   (Belgium)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^k UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF WÜRZBURG   (Germany)

^m SAN RAFFAELE HOSPITAL   (Italy)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^o UNIVERSITY OF BOLOGNA   (Italy)

^p UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^q NEW YORK PRESBYTERIAN HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PRDM1 PROTEIN, HUMAN; PROTEIN P53; PROTEIN TYROSINE KINASE; REPRESSOR PROTEIN; TP53 PROTEIN, HUMAN;

ANAPLASTIC LARGE CELL LYMPHOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLIMP1 TUMOR SUPPRESSOR GENE; CHROMOSOME 17P; CHROMOSOME 6Q; CLINICAL OUTCOME; CONTROLLED STUDY; DNA FINGERPRINTING; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; PRDM1 TUMOR SUPPRESSOR GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; TUMOR SUPPRESSOR GENE; ADOLESCENT; ADULT; AGED; ANIMAL; CANCER TRANSPLANTATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LARGE CELL LYMPHOMA; MIDDLE AGED; NONOBESE DIABETIC MOUSE; T CELL LYMPHOMA; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, T-CELL; MALE; MICE; MICE, INBRED NOD; MIDDLE AGED; NEOPLASM TRANSPLANTATION; RECEPTOR PROTEIN-TYROSINE KINASES; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84891544479     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-497933     Document Type: Article

References (50)

1. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
2. Fornari A, Piva R, Chiarle R, Novero D, Inghirami G. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? Hematol Oncol. 2009;27(4):161-170.
3. Savage KJ, Harris NL, Vose JM, et al; International Peripheral T-Cell Lymphoma Project. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK1 ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496-5504.
4. Barreca A, Lasorsa E, Riera L, et al; European T-Cell Lymphoma Study Group. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol. 2011;47(1):R11-R23.
5. Boi M, Stathis A, Zucca E, Inghirami G, Bertoni F. Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells. Cancer Sci. 2012;103(8):1397-1404.
6. Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia. 2009;23(3):574-580.
7. Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117(3): 915-919.
8. Pham-Ledard A, Prochazkova-Carlotti M, Laharanne E, et al. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases. J Invest Dermatol. 2010;130(3):816-825.
9. Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011; 24(4):596-605.
10. Ott G, Katzenberger T, Siebert R, et al. Chromosomal abnormalities in nodal and extranodal CD301 anaplastic large cell lymphomas: infrequent detection of the t(2;5) in extranodal lymphomas. Genes Chromosomes Cancer. 1998;22(2):114-121.
11. Zettl A, Rüdiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol. 2004;164(5):1837-1848.
12. Salaverria I, Beà S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol. 2008;140(5):516-526.
13. Youssif C, Goldenbogen J, Hamoudi R, et al. Genomic profiling of pediatric ALK-positive anaplastic large cell lymphoma: a Children's Cancer and Leukaemia Group Study. Genes Chromosomes Cancer. 2009;48(11):1018-1026.
14. Rinaldi A, Kwee I, Young KH, et al. Genome-wide high resolution DNA profiling of hairy cell leukaemia. Br J Haematol. 2013;162(4):566-569.
15. Chigrinova E, Rinaldi A, Kwee I, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome [published online ahead of print September 4, 2013]. Blood.
16. Mensah AA, Rinaldi A, Ponzoni M, et al. Absence of NOTCH1 gene mutations in MALT lymphomas. Br J Haematol. 2012;157(3):382-384.
17. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-ofheterozygosity data. Bioinformatics. 2004;20(8): 1233-1240.
18. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002; 18(11):1427-1431.
19. Garcia JF, Roncador G, García JF, et al. PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica. 2006;91(4):467-474.
20. Inghirami G, Macri L, Rosati S, Zhu BY, Yee HT, Knowles DM. The Reed-Sternberg cells of Hodgkin disease are clonal. Proc Natl Acad Sci U S A. 1994;91(21):9842-9846.
21. Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006; 203(2):311-317.
22. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JA. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res. 2007;35(Web Server issue):W71-W74.
23. Bonetti P, Testoni M, Scandurra M, et al. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma [published online ahead of print August 7, 2013]. Blood.
24. Tabbo F, Barreca A, Machiorlatti R, et al. Humanized NOD/Scid/IL2g2/2 tumor grafts recapitulate primary anaplastic large cell lymphoma. Annual meeting of the American Association for Cancer Research; April 6-10, 2013; Washington, DC. Abstract 3853.
25. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.
26. Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK1 anaplastic largecell lymphoma. Blood. 2006;108(8):2796-2803.
27. Honorat JF, Ragab A, Lamant L, Delsol G, Ragab-Thomas J. SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood. 2006;107(10):4130-4138.
28. Lawrie CH. MicroRNAs and lymphomagenesis: a functional review. Br J Haematol. 2013;160(5): 571-581.
29. Merkel O, Hamacher F, Laimer D, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)1 and ALK-anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A. 2010;107(37): 16228-16233.
30. Cretney E, Xin A, Shi W, et al. The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat Immunol. 2011;12(4):304-311.
31. Liu C, Iqbal J, Teruya-Feldstein J, et al. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma [published online ahead of print June 25, 2013]. Blood.
32. Wang L, Toomey NL, Diaz LA, et al. Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression. J Virol. 2011;85(16):8328-8337.
33. Trotta R, Chen L, Costinean S, et al. Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood. 2013;121(16):3126-3134.
34. Pedersen IM, Otero D, Kao E, et al. Onco-miR-155 targets SHIP1 to promote TNFalphadependent growth of B cell lymphomas. EMBO Mol Med. 2009;1(5):288-295.
35. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A. 2009; 106(17):7113-7118.
36. Xu-Monette ZY, Medeiros LJ, Li Y, et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012;119(16): 3668-3683.
37. Cesarman E, Inghirami G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol. 1993;143(3): 845-856.
38. Rassidakis GZ, Thomaides A, Wang S, et al. p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma. Leukemia. 2005;19(9):1663-1669.
39. Hübinger G, Müller E, Scheffrahn I, et al. CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene. 2001;20(5):590-598.
40. Drakos E, Atsaves V, Schlette E, et al. The therapeutic potential of p53 reactivation by nutlin-3a in ALK1 anaplastic large cell lymphoma with wild-type or mutated p53. Leukemia. 2009;23(12): 2290-2299.
41. Piva R, Agnelli L, Pellegrino E, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic largecell lymphoma within peripheral T-cell neoplasms. J Clin Oncol. 2010;28(9):1583-1590.
42. Mandelbaum J, Bhagat G, Tang H, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell. 2010;18(6):568-579.
43. Nishikawa K, Nakashima T, Hayashi M, et al. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc Natl Acad Sci U S A. 2010;107(7): 3117-3122.
44. Karube K, Nakagawa M, Tsuzuki S, et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood. 2011;118(12):3195-3204.
45. Küçük C, Iqbal J, Hu X, et al. PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci U S A. 2011; 108(50):20119-20124.
46. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008; 454(7201):226-231.
47. Yang Y, Shaffer AL III, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6): 723-737.
48. Piya S, Moon AR, Song PI, et al. Suppression of IRF4 by IRF1, 3, and 7 in Noxa expression is a necessary event for IFN-γ-mediated tumor elimination. Mol Cancer Res. 2011;9(10): 1356-1365.
49. Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol. 2010;149(4): 484-497.
50. Rao E, Jiang C, Ji M, et al. The miRNA-17;92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia. 2012;26(5): 1064-1072.